Clinical trial
A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Therapy for Luminal-type Breast Cancer
NCT06402435 is registered in ClinicalTrials.gov with Hubei Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Therapy for Luminal-type Breast Cancer
- Lead sponsor
- Hubei Cancer Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 28, 2024
- Completion date
- September 1, 2027
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer